This paper describes the trends in haematopoietic stem cell transplantation (HSCT) activity for children in Europe over the last three decades. We analysed 31 713 consecutive paediatric HSCTs reported by the European Group for Blood and Marrow Transplantation (EBMT) centres between 1970 and 2002. Data were taken from the EBMT registry and were compared according to period and centre category (paediatric or combined). Since 1996, there has been a significant increase in the number of HSCTs performed exclusively by paediatric centres, as well as in the number of alternative donor HSCTs, and in the use of peripheral blood stem cells (Po0.0001). The number of allogeneic HSCTs (allo-HSCTs) for acute lymphoblastic leukaemia, acute myeloblastic leukaemia and chronic myeloid leukaemia remained stable, whereas it increased for myelodysplastic syndromes and lymphomas, and decreased significantly for non-malignant diseases (Po0.0001). Multivariate analysis showed that younger age, human leukocyte antigen genoidentical donors, HSCT performed after 1996 and transplant centres performing more than 10 allo-HSCT/year were all associated with decreased transplant-related mortality
Introduction
Haematopoietic stem cell transplantation (HSCT) has become a well-established therapy for many severe congenital or acquired disorders of the haematopoietic system and for chemo-sensitive, radio-sensitive or immune-sensitive malignancies in children. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] The information derived from large series of consecutive patients treated at several centres offers an opportunity to address issues in the field of HSCT, and provides a resource for evaluating the changes that have occurred over the last few years. Recently, reports from the European Group for Blood and Marrow Transplantation (EBMT) showed different trends for autologous and allogeneic HSCT. Specifically, the number of autologous HSCTs for solid tumours decreased following 1997, while allogeneic HSCTs increased for all indications, with the sole exception of chronic myeloid leukaemia (CML). The haematopoietic stem cell source has expanded, with a more frequent use of peripheral blood cells both in the autologous and in the allogeneic setting. The pool of donors has significantly grown, and there has been increasing use of alternative HSCTs from mismatched family members, or from unrelated volunteers located in one of the expanding worldwide donor pools or cord blood banks. 16 To date, most published reports have analysed data that were obtained by pooling information on both adults and children. There are only few, large-scale studies that report the HSCT strategies used in children. 17, 18 The main aim of this survey was to describe the trends in HSCT activity for paediatric patients in European transplant centres over the last three decades. The second aim was to separately analyse the risk factors for transplantation-related mortality for auto-or allo-HSCT, taking into account patient-, disease-, transplant-related factors and centre effect, which are all associated with the outcomes.
Design and methods

Data collection
Data collection is based on the EBMT registry. The EBMT registry is a voluntary working group of more than 450 mainly European transplant centres that was established in 1970. One of the requisites to participate in this group is the mandatory registration of all consecutive transplants performed by the centre. This registration is made by filling in the minimal essential data (MED-A) form for all consecutive patients. Disease-oriented (MED-B) forms are filled in by several teams. Centres are requested to update their patients' follow-ups yearly, and audits are routinely performed to determine the accuracy of the data. Since 2001, centres can also submit data via Internet by requesting remote data entry access for Project Manager Internet Server (ProMISe).
ProMISe is the central data processing system used by the EBMT. Users can enter and retrieve data directly over a secure Internet connection. All users access the same copy of the entire project, but users have the option to download their own centre's database for reference purposes. Access to the whole database is restricted to the London and Paris offices. Since 1990, patients have been providing informed consent authorizing their personal information to be included in the database for research purposes. The project was approved by the Ethics Board of the EBMT and by the Registry Subcommittee.
Statistical analysis and definitions
Only patients p18 years of age at the time of HSCT were included in this study. The 420 centres that registered children are listed in the Appendix, in alphabetical order by country, city and EBMT centre code. Institutions are classified into two categories: paediatric teams when they treated only children and combined teams when they treated children and adults. Many of them performed both allogeneic and autologous transplantations.
The patients' characteristics, such as diagnosis and age, based on the time period and the centre category were compared using the w 2 test. All P-values are two-sided with type I error rate fixed at 0.05. The Bonferroni correction for multiple comparisons was used. 19 The following patient or graft characteristics were analysed for their potential value on transplant-related mortality (TRM), that was defined as death from any causes in the absence of relapse or progression of primary disease, including infections, toxicities and other nonrelapse or progression causes of death for auto-and allo-HSCT, and also graft-versus-host disease (GvHD) for allo-HSCT: age, diagnosis, type of transplant, total number of pediatric transplants over the whole observation period, median number of transplants per year, team category (only pediatric or combined), year of beginning. With regard to continuous variables (age, year of transplantation, total number of transplants per centre and median number of transplants per year), the median was taken as a cutoff point.
The cumulative incidence of 100-day and 2-year TRM was calculated in a competing risks setting, with relapse or progression being treated as a competing event, while multivariate analyses were based on the proportional hazards model for this subdistribution of competing risks. 20, 21 All the variables that were found to be statistically associated with TRM (Po0.05) in the univariate analysis were included in the multivariate analysis. Moreover, we included in the final model centre characteristics, including centre category, median number of transplants performed per year and total number of transplants performed in the centre. However, as there was a strong correlation between diagnosis solid tumours and centre categories for autografts (see the Results section), we decided to include the diagnosis rather than the centre category in the multivariate analysis for autografts. Statistical analyses were performed with SPSS (Inc., Chicago, IL, USA) and Splus (MathSoft, Inc, Seattle, WA, USA) software packages.
Paediatric population data were obtained from the US census office (http://www.census.gov.) The transplant rate following 1996 was defined as the mean number of transplants performed in each country per one million inhabitants p18 years of age. Transplant rate was assessed separately for auto-and allo-HSCT.
Based on both published experience and expert opinion, any conditioning regimen with 50% or less equivalence to a standard one was defined as reduced intensity conditioning (RIC) regimen. There was wide variability in activity among teams: half of the allotransplants (9304) were performed in 27 centres, each reporting more than 190 allotransplants in the study period, and the other half (9499) were performed in 269 centres each reporting 190 or fewer allotransplants.
22,23
Results
Participating teams and countries
Most patients o16 years of age (71% of auto-HSCTs and 64% of allo-HSCTs) were treated in paediatric centres, whereas most patients 16-18 years of age (61% of autoHSCTs and 51% of allo-HSCTs) were treated in combined centres.
Half of the autotransplants (6446) were performed in 28 centres, each reporting more than 116 autotransplants in the study period, and half (6464) were performed in 365 centres, each reporting fewer than 116 autotransplants.
The number of transplants that were reported following April 1996, by exclusively paediatric centres increased significantly (Pp0.0001), whereas the number of transplants reported by combined centres decreased significantly (Pp0.0001), as compared to the previous period of time.
As far as the countries involved in this programme are concerned, between 1970 and April 1996, 75% of all transplants were performed in five European countries (France, Italy, the United Kingdom, Spain and Germany). As compared to the previous period of time, the number of countries reporting HSCTs performed after April 1996, in patients o18 years of age increased from 38 (27 European and 11 extra-European) to 43 (29 European and 14 extraEuropean). In particular, an increase in the transplant activity in Eastern and extra-European countries was observed. Between 1996 and 2002, the countries reporting the highest allogeneic transplant rates were Israel, Italy, Sweden, Austria and the United Kingdom. During the same period, the highest autologous transplant rates were reported in Italy, France, Spain and Finland.
Type of HSCT Allo-HSCT was the most frequently performed graft. The number of both allo-and auto-HSCTs per year increased up to a maximum of 1520 and 1025, respectively (total 2545) in 1999. This represents a twofold increase over the 1254 HSCTs that were registered in 1991, and a fivefold increase over the 482 HSCTs registered in 1984 (Figure 1 ). Three hundred and sixty-two out of 18 803 allo-HSCTs were performed after an RIC regimen. The percentage of RIC transplants increased by 5% only after the year 2000.
Donor type
Before May 1996, majority of the allografts (70%) were performed from human leukocyte antigen-matched sibling donors (MSD). During the last 10 years of this survey, the number of alternative HSCTs, including volunteer unrelated donor (VUD), partially matched family donor, and cord blood (CB) HSCT increased significantly (Pp0.0001), and reached 61% of the allografts carried out between 1999 and 2002 ( Figure 2 ).
Stem cell source
Bone marrow was the only source of stem cells for allo-and auto-HSCT before 1977 and before 1985, respectively.
Peripheral blood stem cells (PBSCs) were used significantly more often following 1996 (Pp0.0001), as they were utilised in 30% of the allo-HSCTs and 85% of the autoHSCTs performed between 1999 and 2002, respectively. As for allo-HSCTs, PBSCs were collected from 4% and from 26% of matched sibling and haploidentical donors, respectively. PBSC-matched sibling and haploidentical donors were o18 years of age in 57% and in 7% of cases, respectively.
A total of 662 CB transplants from either a related (209) or an unrelated (453) donor were reported following 1988.
Indications
The most frequent indications for HSCT were acute lymphoblastic leukaemia (ALL, 6200 allogeneic, 1965 After 1996, the number of children given allogeneic stem cell transplantation for ALL, AML and CML remained stable, whereas the number of children given allogeneic stem cell transplantation for MDS and lymphomas increased significantly (Po0.0001). The number of children given allo-HSCT for non-malignant diseases decreased significantly (Po0.0001). Moreover, the number of patients given auto-HSCT for ALL and AML decreased, whereas the number of patients given auto-HSCT for solid tumours increased significantly (Po0.0001) (Figure 3 ).
Transplantation-related mortality Allo-HSCT. Cumulative incidence of TRM at day 100 and at 2 years for children given allo-HSCT was 13% and 21%, respectively. Auto-HSCT. Cumulative incidence of TRM at day 100 and at 2 years for children given auto-HSCT was 5 and 9% (P ¼ NS), respectively. Figure 3 Number of transplants by disease and by year. ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; CML, chronic myeloid leukaemia; MDS, myelodysplasia, LYM, lymphoma; ST, solid tumours; NMD, non-malignant diseases; Allo, allogeneic; Auto, autologous. between 1991 and 1994, to 61% between 1999 and 2002 . This was made possible thanks to the creation and expansion of a network that includes 10 million VUDs in 40 registries and 130 000 units in 34 CB banks worldwide. Greater use of transplantation across the histocompatibility barrier has been made possible by techniques allowing extensive T-cell depletion of the graft 6 for children with acute leukaemia or inborn errors who lack an acceptable unrelated donor or cord blood. Several papers have recently reported an improvement over time in outcome for children given alternative HSCTs, thus favouring a wider use of this type of allograft.
11-13 The growing number of teams, and the increased activity that was observed in eastern European countries between 1996 and 2002, represent a change in trend as compared to the past and prove how successful the EBMT outreach programme has been. 24 The present data highlight a significant increase in the use of PBSCs during the last few years, representing 30% of allo-HSCTs and 85% of the auto-HSCTs performed between 1999 and 2002. The use of PBSCs in children given MSD transplants is limited because of the concern of increasing the risk of chronic GvHD. 25 In the autologous setting, the use of PBSCs has completely replaced BM in the treatment of solid tumours owing to the evidence of faster haematopoietic recovery, reduced toxicity and length of hospitalization.
14,15 The use of autologous PBSCs in children with acute leukaemia is not frequent, mainly because of the difficulties in collecting adequate numbers of circulating haematopoietic progenitors, not to mention the still open question concerning whether the use of PBSCs may favour leukaemia recurrence. 4 We observed a stable trend in the use of allo-HSCT for CML, unlike data reported for adults in whom the use of HSCT in CML drastically decreased after the introduction of imatinib mesylate, and in whom most transplants were performed in the advanced phase. 26, 27 This discrepancy can be explained by the fact that we still do not have evidence that imatinib mesylate is curative, and that children have a longer life expectancy.
The increasing number of children with MDS given allo-HSCT is justified by the encouraging results that have been reported with the use of this procedure. 28, 29 The drop in the number of children given allo-HSCT for non-malignant diseases over the study period is difficult to explain.
The number of patients given auto-HSCT for ALL and AML has decreased significantly, whereas the number of patients given auto-HSCT for solid tumours has increased significantly.
Indications to autologous transplantation for ALL are limited to a small subset of patients with either late bone marrow relapse or extramedullary recurrence, 9,10 and the results of studies comparing auto-HSCT and chemotherapy in children with AML are conflicting. 4 We observed an increase in the use of auto-HSCT for paediatric solid tumours, unlike data reported for adults, which recently raised doubts about the efficacy of HSCT for breast cancer patients, thus contributing to a change in the previous trend. 30 The lower TRM that was observed in the last years of the study contributed to making megatherapy followed by HSCT a more acceptable procedure in phase III trials in children with high-risk solid tumours. In addition, there is increasing evidence from prospective studies that megatherapy followed by HSCT indeed contributes to improving the outcome in this subset of patients. Two major, prospective, randomized studies have been designed and initiated by European paediatric oncologists and are currently ongoing for two major indications: neuroblastoma and Ewing tumour. In some other indications, dose escalation strategies appear to be failing, and thus there is an obvious need to develop newer strategies based on innovative, immuno-biological concepts. [31] [32] [33] The decrease in TRM probability that was observed in the centres performing greater numbers of allo-HSCTs highlights the importance of experience and the learning effect, and should lead health authorities to carefully plan transplant activities and to concentrate resources on experienced institutions. Possible exceptions are areas or countries lacking paediatric stem cell transplant units, but having active, government-supported stem cell transplant programmes. In keeping with previous observations, 34, 35 we confirm that competent care for highly specialized procedures, such as HSCT in children, can only be cost-effective when enough procedures are performed at the same centre. Quality control programmes should include separate, welldefined standards for HSCT in children and adolescents up to the age of 18.
In summary, major changes have occurred over the last few years. Knowledge of these data provides a basis for decision-making in health-care planning and for patient counselling. In detail, they suggest that haematopoietic HSCT in children and adolescents up to the age of 18 years should be performed by a dedicated transplant team and should be treated within a paediatric programme. 
References
